ONO-7913-04: ONO-7913 Phase 1 Study

ONO-7913: ONO-7913 Phase 1 Study; An open-label, uncontrolled study of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051210038

Enrollment

Registered

2021-06-15

Start date

2021-09-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced or recurrent colorectal cancer

Interventions

Administration of ONO-7913 and ONO-4538 with FOLFOX and Bevacizumab or Cetuximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Unresectable advanced or recurrent colorectal cancer 2. Life expectancy of at least 3 months 3. Patients with ECOG performance status 0 or 1

Exclusion criteria

Exclusion criteria: 1. Patients with severe complication 2. Patients with multiple primary cancers

Design outcomes

Primary

Measure	Time frame
Tolerability, safety	—

Contacts

Public ContactMedical Center

Ono Pharmaceutical Co.,LTD

clinical_trial@ono.co.jp+81-120626190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026